Arcadia vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Population health and value-based care analytics platform aggregating clinical and claims data for health systems and ACOs. Burlington MA, raised $100M+.
About
Arcadia is a healthcare data and analytics company that helps health systems, ACOs, and payers succeed in value-based care arrangements. Headquartered in Burlington, Massachusetts, and having raised more than $100 million from investors including Andreessen Horowitz, Arcadia's platform aggregates clinical data from EHRs, claims data from payers, and social determinants of health data from community sources into a unified longitudinal patient record. This master data layer powers care management workflows, quality measurement, network analytics, and financial performance reporting for value-based care programs.\n\nArcadia's differentiation lies in its ability to normalize and harmonize data from dozens of disparate EHR and claims sources at scale, giving health system leaders and ACO operators a complete and accurate view of their attributed populations. The platform supports MSSP, Medicare Advantage, commercial value-based contracts, and Medicaid managed care programs, helping organizations track performance against quality metrics like HEDIS and CMS Stars while identifying high-risk members for intervention. Embedded care management tools allow clinical teams to act directly on the insights the platform surfaces.\n\nThe company has positioned itself as a strategic analytics partner for complex, multi-entity health systems that cannot rely on a single EHR vendor for population health insights. Arcadia competes with health IT giants like Health Catalyst and Optum as well as specialty vendors, and has continued to grow its customer base among large regional health systems and national provider organizations participating in risk-bearing contracts.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.